Form 4: Cue Biopharma Director Jill Marie Broadfoot Awarded 48,800 Stock Options

Cue Biopharma, Inc. Director Jill Marie Broadfoot has been granted 48,800 stock options as part of the company's Director Compensation Policy, aligning her interests with shareholder value.

Summary

• Jill Marie Broadfoot, a Director at Cue Biopharma, Inc. (CUE), was granted 48,800 stock options.
• The stock options have an exercise price of $0.62 per share.
• The grant date for these options was June 4, 2025.
• The options are scheduled to vest over three years, with one-third vesting on the one-year anniversary of the grant date (June 4, 2026) and the remaining balance vesting in eight equal quarterly installments thereafter.
• The expiration date for these stock options is June 3, 2035.
• This award was made pursuant to the Issuer's Director Compensation Policy.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments for the company.

Positives

• The grant of stock options to Director Jill Marie Broadfoot aligns her financial interests with the long-term performance and shareholder value of Cue Biopharma, Inc.
• The award is part of a structured Director Compensation Policy, indicating a formalized approach to executive and board incentives.

Future Outlook

The vesting schedule of the stock options over three years indicates a long-term incentive structure for the director, aiming to retain talent and align their performance with the company's future growth.

Management Comments

• The stock option award was granted pursuant to the Issuer's Director Compensation Policy.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract and retain experienced board members and align their interests with long-term company performance.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a standard industry practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule over three years is typical for long-term incentive plans, comparable to those seen at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-employee directors, aiming to foster sustained commitment.

Corporate Governance

Related Party Transactions

• The grant of 48,800 stock options to Jill Marie Broadfoot, a Director of Cue Biopharma, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The stock option grant aims to align the director's interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the overall governance and incentive philosophy of the company.

Next Steps

• Continued vesting of the granted stock options according to the specified schedule.

Key Dates

Keywords

Cue Biopharma, CUE, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Biopharma, Corporate Governance